ライフサイエンスコーパス: flupentixol

1 to -0.44; sulpiride) to 0.04 (-0.39 to 0.47; flupentixol).

2 antially affected in the presence of cis-(Z)-flupentixol.

3 p-mediated drug transport by both isomers of flupentixol.

4 S) of the dopamine receptor antagonist alpha-flupentixol.

5 ent reward deliveries was also unaffected by flupentixol.

6 Rats were then injected systemically with flupentixol, a dopamine receptor antagonist, or vehicle

7 cis(Z)-Flupentixol, a modulator of Pgp function, preferentially

8 on of Pgp-mediated drug transport by cis-(Z)-flupentixol, a thioxanthene derivative, occurs through a

9 howed greater response suppression following flupentixol administration than rats experiencing no shi

10 mechanism by which the Pgp modulator cis-(Z)-flupentixol allosterically inhibits drug transport.

11 based allosteric modulators, such as cis-(Z)-flupentixol and its closely related analogs, induce rege

12 nthene-based Pgp modulators, such as cis-(Z)-flupentixol and its closely related analogues, effective

13 ibition of drug transport by both isomers of flupentixol and plays an important role in stimulation a

14 ibit P-GP and that the P-GP inhibitors trans-flupentixol and quinidine inhibit VMAT2.

15 In F983A the stimulatory effect of cis(Z)-flupentixol and the inhibitory effect of trans(E)-flupen

16 s accessible and responsive to modulation by flupentixol (and its closely related analogs), which can

17 ug transport by the cis and trans isomers of flupentixol are mediated through a common site of intera

18 such as cyclosporin A and verapamil, cis-(Z)-flupentixol does not interfere with substrate ([(125)I]i

19 o -0.39; clozapine) to -0.10 (-0.45 to 0.25; flupentixol), for depressive symptoms (19 683 participan

20 dissociates susceptibility to inhibition by flupentixol from drug translocation, indicating the allo

21 Interestingly, although flupentixol had a modest effect on the immediate respons

22 Specifically, flupentixol had a stronger suppressive effect in group F

23 The allosteric modulator cis-(Z)-flupentixol has no effect on [alpha-(32)P]-8-azido-ATP b

24 Finally, cis-(Z)-flupentixol has no effect on dissociation of [alpha-(32)

25 Oral flupentixol (HR, 0.92; 95% CI, 0.74-1.14), quetiapine (H

26 tant F983A that is impaired in modulation by flupentixols, indicating involvement of the allosteric m

27 cis-(Z)-Flupentixol-induced complex formation requires involveme

28 isomers of the dopamine receptor antagonist flupentixol inhibit drug transport and reverse drug resi

29 ion, indicating the allosteric nature of the flupentixol interaction.

30 Allosteric modulation by cis-(Z)-flupentixol involves a conformational change in Pgp dete

31 12 of Pgp that impairs inhibition by cis-(Z)-flupentixol of Pgp-mediated drug transport also affects

32 date-trapped Pgp shows protection by cis-(Z)-flupentixol of two Pgp fragments (approximately 60 kDa)

33 tic monotherapies, including chlorprotixene, flupentixol, olanzapine, zuclopenthixol, quetiapine, per

34 ntixol and the inhibitory effect of trans(E)-flupentixol on ATP hydrolysis and [125I]IAAP labeling we

35 the nonspecific dopamine receptor antagonist flupentixol on response invigoration and action bias in

36 MPTP and a P-GP inhibitor (quinidine, trans-flupentixol or cyclosporine A), the elimination of MPP(+

37 croinjections of the dopamine antagonist cis-flupentixol or the cholinergic antagonist atropine into

38 n of either the dopamine receptor antagonist flupentixol or the nicotinic receptor antagonist mecamyl

39 s injection of either a dopamine antagonist (flupentixol) or an opioid antagonist (naloxone) into the

40 At test, we found that flupentixol pretreatment blocked the response invigorati

41 [125I]IAAP labeling by cis(Z)- and trans(E)-flupentixol, respectively.

42 hibitor nisoxetine or D2 receptor antagonist flupentixol significantly increased sugar-evoked dopamin

43 A second round of flupentixol tests was conducted using the rats' maintena

44 , which is impaired in modulation by cis-(Z)-flupentixol, the modulator has a minimal effect on subst

45 o shift in cost (group FR-10/FR-10), whereas flupentixol treatment had no effect on rats experiencing

46 C-site was increased 5- to 6-fold by cis(Z)-flupentixol without any effect on the N-site.